-
Arnold Pharma announces that Buparlisib (AN2025) for the treatment of recurrent or metastatic head and neck cancer has completed the first patient in the global phase III clinical trial | Yimai Meng broke the news
Time of Update: 2021-04-23
S. -Arnold Pharma, an innovative global biopharmaceutical company focused on tumor treatment, recently announced its oral PI3K inhibitor Buparlisib (AN2025) combined with paclitaxel for the treatment of relapse or metastasis The global multi-center phase III clinical trial (study name BURAN) of squamous cell carcinoma of the head and neck has successfully completed the first patient administration in Shanghai Oriental Hospital, China, opening the world's first PI3K drug in the field of head and neck cancer treatment.
-
Dialogue with Professor Ma Fei: In the new era of chemotherapy, patients with advanced breast cancer usher in both overall survival and quality of life benefits
Time of Update: 2021-04-23
On the occasion of the event of Cancer Prevention and Treatment Week-"Caring for Patients with Advanced Breast Cancer and the Launching Meeting of Quality of Life Research", the "medical community" specially invited Professor Ma Fei from the Cancer Hospital of the Chinese Academy of Medical Sciences to express opinions on related topics.
-
How important is nutritional support for cancer patients?
Time of Update: 2021-04-23
End-stage cancer patients refer to patients who have lost the indications of conventional anti-tumor treatment, including surgery, radiotherapy, chemotherapy and molecular targeted drug therapy.
-
Case Sharing|To live up to the "Tuo", Tuoyi treats nasopharyngeal carcinoma with high risk of recurrence and metastasis up to CR!
Time of Update: 2021-04-23
Table 2 Results of the second re-examination (after CCRT, in adjuvant treatment with teriprizumab) Case analysis The patient was diagnosed as "nasopharyngeal undifferentiated non-keratinizing carcinoma" (T3N3M0, stage IVa), with an EBV DNA of 1.
-
"Top Ten Progresses in the Cancer Field Most Concerned by the Public in 2020" Released
Time of Update: 2021-04-23
*Only for medical professionals to read and refer to the annual list of China's cancer prevention and treatment field April 15th, during the "27th National Cancer Prevention and Treatment Promotion Week", the science professional committee of the Chinese Anti-Cancer Association joined the Xinhuanet client and Xinhuanet big data The center, based on the Xinhua Ruisi data cloud image analysis platform, jointly released the "Top Ten Progresses in the Cancer Field of the Most Concerned by the Public in 2020".
-
Molecular Cancer | Continuous progress!
Time of Update: 2021-04-23
In summary, this study reveals a potential new mechanism for the deregulation of miR-144/miR-451a clusters and the crosstalk between malignant cells and tumor-associated macrophages (TAM) in HCC, providing new insights into the pathogenesis and diagnostic strategies of HCC .
-
Genome Medicine | Zhao Quan's research group at Nanjing University discovers new histone modification recognition effector molecules and cancer treatment applications
Time of Update: 2021-04-23
On April 14, 2021, Zhao Quan's team from the School of Life Sciences, Nanjing University published a research paper PRMT1-mediatedH4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling in the internationally renowned journal Genome Medicine (IF=10.
-
Schlafen 5: A new target for the treatment of pancreatic cancer
Time of Update: 2021-04-23
Studies have confirmed that in the in vivo PDAC model, the targeted deletion of SLFN5 does cause the decline of PDAC cell proliferation and inhibit the growth of PDAC tumors.
-
After two relapses!
Time of Update: 2021-04-23
Professor Zhang Bingzhong: Most patients with ovarian cancer can achieve complete remission after the initial treatment, but about 80% of patients will relapse, with an average recurrence time of about 18 months.
-
Professor Huang He: Another breakthrough in the treatment of B-NHL with new CAR-T cells|The First National Lymphocytic Disease Conference of Chinese Medical Association
Time of Update: 2021-04-23
2. CD19/CD22 sequential CAR-T cell therapy In addition, Professor Huang He introduced that the team of Professor Zhou Jianfeng from Tongji Hospital of Huazhong University of Science and Technology used CD19-CAR-T cells sequential CD22-CAR-T cells to treat relapsed/refractory B Cell tumor patients have also achieved good results: CD19/CD22 CAR-T cells have been expanded significantly, the overall response rate (ORR) is 72.
-
Tongxin Association Case No. 5 | Multidisciplinary collaboration to help high-risk god mothers survive long-term-high-risk neuroblastoma long-term survival case sharing
Time of Update: 2021-04-23
According to the neuroblastoma stage IV high-risk group, the outer hospital underwent a course of CAV (cyclophosphamide, pirarubicin, vincristine) chemotherapy on December 27, 2013, and the symptoms of bone pain disappeared after chemotherapy.
-
Science Advances | Continuous progress!
Time of Update: 2021-04-23
In addition, on November 4, 2020, the Sun Jin team of Shenyang Pharmaceutical University published an online study titled "Trisulfide bond–mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity" in Science Advances.
-
Molecular Cancer | Huazhong University of Science and Technology Jiang Guosong/Zhang Xiaoping discovers new potential therapeutic targets for bladder cancer
Time of Update: 2021-04-23
In conclusion, this study determined that exon circular circPTPRA is a new type of tumor suppressor, which inhibits the progression of cancer by endogenously blocking IGF2BP1's recognition of m6A-modified RNA, indicating that circPTPRA can be used as a therapeutic effect for patients with bladder cancer.
-
Verbutuximab adds another indication!
Time of Update: 2021-04-23
The ALCANZA study is an international, multi-center, randomized, open-label Phase III trial, carried out in 52 medical centers in 13 countries/regions around the world, to evaluate the use of new drugs BV and traditional therapies in patients with CD30-positive CTCL The efficacy and safety of [7].
-
Sun Yat-sen University's Fu Liwu Group AS: Aldehyde dehydrogenase 2 mediates alcohol-induced immune escape in colorectal cancer
Time of Update: 2021-04-23
Fu Liwu's research group at the State Key Laboratory of Oncology in South China, Sun Yat-sen University found that acetaldehyde dehydrogenase 2 (ALDH2) plays a key role in promoting alcohol-mediated immune escape from bowel cancer and promoting tumor progression.
-
First-line treatment of advanced gastric cancer!
Time of Update: 2021-04-23
Recent popular reports from Yimaike ★ Nanjing · Big coffee gathered in May 2021 nucleic acid drug development forum announced schedule ★ May Nanjing 2021 nucleic acid drug development forum is about
-
Gut: If this test is positive, the risk of death from colorectal cancer is doubled without colonoscopy!
Time of Update: 2021-04-23
After reviewing and analyzing the data of the Veneto Region CRC screening project for more than ten years, it was found that the fecal immunochemical test ( Among the participants with FIT positive, those who refused colonoscopy had twice the risk of death due to CRC as those who received timely colonoscopy.
-
2021 CSCO Breast Cancer Guidelines: Interpretation of the updated key points of HER2+ neoadjuvant treatment for early breast cancer | 2021 CSCO BC
Time of Update: 2021-04-23
In view of the fact that the concept of “neoadjuvant treatment for T1c patients” has not been verified by clinical research and practice, the CSCO breast cancer guidelines still adopt the most advanced and feasible selection criteria currently considered, that is, for HER2+, T≥2 or N≥1 The patient was given neoadjuvant therapy.
-
Molecular Cancer | Soochow University Zhang Lifeng/Chen Yan discovered the key role of circular RNA in triple-negative breast cancer
Time of Update: 2021-04-23
iNature chemotherapy resistance is the main reason for clinical treatment failure and poor prognosis of triple negative breast cancer (TNBC).
On March 1, 2021, Zhang Lifeng and Chen Yan from Soochow University published an online report titled "CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K in Molecular Cancer (IF=15.
-
Survival from a dead end: advanced triple-negative breast cancer discovered driver gene mutations, targeted therapy to relieve the condition
Time of Update: 2021-04-23
Two years after the operation, the patient was re-examined and found suspicious lesions in the right lung, which was confirmed by needle biopsy as a metastasis of triple-negative breast cancer.
Verofenib is a targeted drug for the BRAF gene V600E mutation site, but it has not been indicated for triple-negative breast cancer.
